Targeting hepatic glucokinase in type 2 diabetes: weighing the benefits and risks.
Agius
Loranne
L
Institute of Cellular Medicine, The Medical School, Newcastle University, Newcastle upon Tyne, UK. loranne.agius@ncl.ac.uk
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D002352:Carrier Proteins / Q000235:genetics / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism / Q000628:therapy*; D005941:Glucokinase / Q000235:genetics / Q000378:metabolism*; D005947:Glucose / Q000378:metabolism; D008099:Liver / Q000201:enzymology / Q000378:metabolism; D008297:Male; D008954:Models, Biological; D051381:Rats; D011924:Rats, Zucker
D001786:Blood Glucose; D002352:Carrier Proteins; C080906:glucokinase regulatory protein; D005941:Glucokinase; D005947:Glucose